secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-06-15T23:59:59+00:00
Accession:  0001683168-22-004361
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte defends board and strategy against Iroquois Capital; accelerates pancreatic cancer trial
--------------------------------------------------------------------------------

- Company expects to begin Phase 2b pancreatic cancer trial immediately upon FDA lifting clinical hold, saving ~6 months.
- Board plans to add capital markets experience; Iroquois has not recommended any candidate despite offer.
- New executive compensation agreements tie cash and equity bonuses to achievement of corporate goals.
- Company raised ~$90M in two capital raises and uplisted to Nasdaq; cash provides strategic advantage.
- Company reiterates strategy will deliver higher shareholder value over time; rejects Iroquois' characterizations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/0001683168-22-004361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822004361/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-004361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer